Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Surgical Idiopathic Intracranial Hypertension Treatment Trial (SIGHT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03501966
Recruitment Status : Recruiting
First Posted : April 18, 2018
Last Update Posted : March 13, 2019
Sponsor:
Collaborators:
National Eye Institute (NEI)
University of Iowa
Icahn School of Medicine at Mount Sinai
Information provided by (Responsible Party):
Jaeb Center for Health Research

Brief Summary:
Randomized trial of adults (≥18 years old) with idiopathic intracranial hypertension and moderate to severe visual loss without substantial recent treatment who are randomly assigned to (1) medical therapy, (2) medical therapy plus ONSF, or (3) medical therapy plus VPS. The primary outcome is visual field mean deviation change at first of Month 6 (26 weeks) or time of treatment failure of the eligible eye(s), followed by a continuation study to assess time to treatment failure. The determination of eligible eye(s) is based on meeting the eligibility criteria at baseline.

Condition or disease Intervention/treatment Phase
Idiopathic Intracranial Hypertension Drug: Acetazolamide Procedure: Optic Nerve Sheath Fenestration Procedure: Ventriculoperitoneal CSF Shunting Phase 3

Detailed Description:

After signing the informed consent form, potential subjects will be assessed for eligibility, including eliciting medical and neurologic history, measurement of best-corrected visual acuity, visual field testing, ophthalmoscopy with optic disc edema grading, physical examination, and Optical Coherence Tomography (OCT). Questionnaires will be completed. Blood will be drawn for complete blood count (CBC), electrolytes, liver function tests, renal function tests, amylase if not done as part of routine care within 4 weeks and a pregnancy test will be performed (women of childbearing potential).

The Screening Visual Field will use a size III stimulus. Two visual field examinations using a size V stimulus will need to be performed at either the Screening or Baseline Visits. The size V fields will be sent to the Visual Field Reading Center (VFRC) to confirm eligibility or determine that testing must be repeated for the subject.

Eligible individuals will be randomly assigned with equal allocation to one of 3 treatment groups: (1) medical therapy, (2) medical therapy plus ONSF, or (3) medical therapy plus VPS. Acetazolamide should be started on the day of randomization. Surgery should be performed as soon as possible, ideally within 3 days of randomization, but not more than 7 days.

Medical therapy will consist of a low sodium weight loss diet and acetazolamide with or without furosemide. Treatment will start with acetazolamide 2 grams per day, with the dose increased as tolerated up to 4 grams per day. If there is no clinical improvement after 2 weeks of maximal dosage of acetazolamide, furosemide will be started at a dose of 40 mg per day (along with potassium) and titrated up to 160-200 mg per day. Pharmacotherapy will be tapered when there is improvement in the papilledema grade, substantial improvement in the PMD and improvement in symptoms or when there is a safety concern.

The primary outcome is measured at the first of 6 months (26 weeks) or time of treatment failure. During the randomized trial, follow-up visits will occur after weeks 4, 8, 16, and 26 (± 7 days). Safety visits will occur after weeks 1 and 2 (± 4 days). Additional office visits may occur as needed. Phone contacts will occur after 12 and 20 weeks (±7 days).

After the 6-month primary outcome visit, subjects will transition to the Treatment Failure Identification Phase for up to 3 years. Ongoing treatment will continue following the guidelines for the first six months as long as treatment failure criteria are not met at which time treatment will be at the discretion of the Site Investigator. Investigators are urged to employ treatments from another arm of the study before other treatments under these circumstances.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 180 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Subjects will be randomly assigned with equal allocation to one of the three treatment groups. Using a permuted block design, randomization will be stratified by PMD (average of 2 size V stimulus tests) in the eligible eye(s) (-6 dB to >-12 dB; -12 dB to >-20 dB; -20 dB to -27 dB). If a subject has two eligible eyes, the average PMD of the two eyes will be used for stratification.
Masking: Single (Outcomes Assessor)
Masking Description: Partially-masked technicians for perimetry, fundus photos, OCT, and refraction/ visual acuity
Primary Purpose: Treatment
Official Title: Randomized Trial of Medical Therapy (MT) vs. MT Plus Optic Nerve Sheath Fenestration vs. MT Plus Ventriculoperitoneal Cerebrospinal Fluid Shunting in Subjects With Idiopathic Intracranial Hypertension and Moderate to Severe Visual Loss
Actual Study Start Date : February 6, 2019
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : June 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Acetazolamide including Diet

Subjects will use 250 mg tablets of acetazolamide, divided into two doses, taken with meals. Initial dose will be 1,000 mg twice per day and increased per titration schedule (Table 6 in protocol).

Dietary consultation will include advising subjects to adopt a low sodium weight reduced diet.

Drug: Acetazolamide
Medical therapy including diet
Other Names:
  • Diamox
  • water pill
  • diuretic

Active Comparator: Optic Nerve Sheath Fenestration

Acetazolamide including Diet plus Optic Nerve Sheath Fenestration (ONSF) Subjects will use 250 mg tablets of acetazolamide, divided into two doses, taken with meals. Initial dose will be 1,000 mg twice per day and increased per titration schedule (Table 6 in protocol).

Dietary consultation will include advising subjects to adopt a low sodium weight reduced diet.

ONSF performed by qualified, certified orbital surgeon using either a medial or supero-medial lid crease approach. ONSF will be performed in one or both eyes, depending on criteria.

Procedure: Optic Nerve Sheath Fenestration
Medical therapy including diet + optic nerve sheath fenestration
Other Name: ONSF

Active Comparator: Ventriculoperitoneal CSF Shunting

Acetazolamide including Diet plus Ventriculoperitoneal CSF Shunting (VPS) Subjects will use 250 mg tablets of acetazolamide, divided into two doses, taken with meals. Initial dose will be 1,000 mg twice per day and increased per titration schedule (Table 6 in protocol).

Dietary consultation will include advising subjects to adopt a low sodium weight reduced diet.

VPS performed by qualified, certified neurosurgeon using a frameless image-guided stereotactic system and positioning a shunt catheter in the lateral ventricle of the cerebral hemisphere not associated with speech. The catheter will be connected to an adjustable valve, and a distal shunt system will be placed in the peritoneal cavity.

Procedure: Ventriculoperitoneal CSF Shunting
Medical therapy including diet + ventriculoperitoneal CSF Shunting
Other Names:
  • VPS
  • CSF Shunt Surgery




Primary Outcome Measures :
  1. Perimetric Mean Deviation (PMD) [ Time Frame: 6 months ]
    Change from baseline to first of Month 6 (Week 26) or time of treatment failure in PMD (perimetric mean deviation) in eligible eye(s) with the size V stimulus


Secondary Outcome Measures :
  1. Treatment Failure [ Time Frame: up to 3 years ]
    Time from randomization to treatment failure

  2. Cerebrospinal Fluid (CSF) Opening Pressure [ Time Frame: 6 months ]
    Change in CSF opening pressure measurement by lumbar puncture

  3. Papilledema Grade [ Time Frame: 6 months ]
    Change in papilledema grade

  4. OCT Retinal Nerve Fiber Layer Thickness [ Time Frame: 6 months ]
    Change in retinal nerve fiber layer thickness

  5. OCT Total retinal thickness [ Time Frame: 6 months ]
    Change in total retinal thickness

  6. Visual Acuity (VA) using Early Treatment Diabetic Retinopathy Study (ETDRS) chart [ Time Frame: 6 months ]
    Change in VA scores, determined by baseline VA of better than 20/200 (39 or more letters correct) and worsening indicated by less correct letters

  7. Quality of Life (QoL) 36 Item Short Form Health Survey (SF-36v2) [ Time Frame: 6 months ]
    Changes in QoL as measured by responses

  8. Quality of Life (QoL) Visual Function Questionnaire (VFQ-25) [ Time Frame: 6 months ]
    Changes in QoL as measured by responses

  9. Quality of Life (QoL) 10-item neuro-ophthalmic supplement to the VFQ-25 [ Time Frame: 6 months ]
    Changes in QoL as measured by responses

  10. Headaches [ Time Frame: 6 months ]
    Headache Impact Test (HIT-6) Inventory



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 63 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject Eligibility Criteria Inclusion Criteria

    1. Diagnosis of IIH by modified Dandy criteria (Table 4)
    2. Age 18 to <64 years at time of consent
    3. Age 18 to <61 years at time of diagnosis (time of diagnosis is the time at which the patient meets the modified Dandy criteria, usually after the lumbar puncture results are reviewed)
    4. Presence of bilateral papilledema
    5. Lumbar puncture within 6 weeks of screening visit or completed as part of screening: Opening CSF pressure >250 mmH2O or 200 to 250 mmH2O; and at least one of the following:

      • Pulse synchronous tinnitus
      • Cranial nerve VI palsy
      • Echography for disc drusen negative and no other disc anomalies mimicking disc edema present
      • Magnetic Resonance Venography (MRV) with lateral sinus collapse/stenosis, partially empty sella turcica on coronal or sagittal views of MRI, and optic nerve sheaths with filled out CSF spaces next to the globe on T2 weighted axial MRI scans If the patient was treated with intracranial pressure lowering agents (e.g., acetazolamide) prior to obtaining a lumbar puncture, the agent(s) must be discontinued for at least 24 hours prior to performing the diagnostic lumbar puncture.
    6. At least one eye meeting all eligible eye inclusion criteria and no exclusion criteria.
    7. Able to provide informed consent
    8. Investigator believes participant is a good candidate for the study, including the probability of returning for follow-up.
  • Eye-Level Eligibility Criteria Subjects must have at least one eye meeting all of the inclusion criteria and none of the exclusion criteria.

If both eyes meet eligibility criteria at the baseline examination, both will be included in the primary outcome analysis.

Inclusion

  1. Visual field loss meeting the following criteria based on two full threshold 24-2 size V tests reviewed by the VFRC:

    • PMD from -6 decibel (dB) to -27 dB
    • Reproducible visual loss present on automated perimetry including no more than 15% false positive response
  2. Visual acuity better than 20/200 (39 or more letters correct)

Exclusion Criteria:

  • Subject Exclusion Criteria Exclusion Criteria

    1. Treatment of IIH within the past 3 months with either (1) the maximally tolerated dosage of acetazolamide for at least one week or (2) more than one month of acetazolamide with a cumulative dosage of more than 30 grams 'Maximally-tolerated dose' is defined as dosage was reached where dosage could not be increased further either because of side effects or because a daily total dosage of 4 grams per day was reached.

      If individual discontinued acetazolamide in the past due to side effects, individual is only eligible if investigator believes that the individual is likely to tolerate acetazolamide, as it will be prescribed in the study.

    2. Treatment of IIH within the past 3 months with either (1) the maximally tolerated dosage of methazolamide for at least one week or (2) more than one month of methazolamide with a cumulative dosage of more than 3 grams 'Maximally-tolerated dose' is defined as dosage was reached where dosage could not be increased further either because of side effects or because a daily total dosage of 400 mg per day was reached.
    3. Treatment with topiramate within two months and average cumulative dosage for the preceding month of more than 700 mg per week
    4. Previous surgery for IIH, including ONSF, CSF shunting, subtemporal decompression, or venous sinus stenting; gastric surgery for obesity is allowed
    5. Abnormalities on neurologic examination except for papilledema and its related visual loss or cranial nerve VI to VII paresis; if other abnormalities are present, the patient will need to be discussed with the Study Director (SD) for study entry.
    6. Abnormal CT or MRI scan (intracranial mass, hydrocephalus, dural sinus thrombus, or arteriovenous malformation) other than findings known to occur with increased intracranial pressure. Abnormalities on MRI that are not known to cause increased intracranial pressure are acceptable.
    7. Abnormal CSF contents: increased cells: > 8 cells; elevated protein: > 45 mg%; low glucose: < 30 mg% (If the lumbar puncture produces a cell count compatible with a traumatic needle insertion, the patient does not need to be excluded if the CSF white blood cell count (WBC) after correction is 8 cells/mm3 or less - see Manual of Procedures (MOP) for calculation. If > 8 cells or > 45mg% in CSF protein are documented in the CSF or calculated after conversion from a traumatic lumbar puncture, the patient can be discussed with the Study Director for possible inclusion.)
    8. Abnormal blood work-up indicating a medical or systemic condition associated with raised intracranial pressure
    9. Diabetes mellitus with diabetic retinopathy
    10. Ingestion of a drug or substance, or presence of a disorder, that has been associated with increased intracranial pressure within 2 months of diagnosis, such as lithium, vitamin A related products (e.g., Retin-A), or various cyclines (see MOP for conditions and drugs)
    11. Laboratory test results showing severe anemia, leukopenia or thrombocytopenia, renal failure, or hepatic disease, based on the Site Investigator's judgment
    12. Other condition requiring oral, I.V. or injectable steroids (nasal, inhaled, or topical steroids are allowed since the systemic effects are small)
    13. Presence of a medical condition that would contraindicate use of acetazolamide or furosemide or significantly increase surgical risk
    14. Pregnancy or unwillingness for a subject of childbearing potential to use contraception during the first 6 months of the study Women of childbearing potential must use an acceptable form of birth control during the first 6 months of the study. Acceptable forms include oral contraceptives, transdermal contraceptives, diaphragm, intrauterine devices (IUDs), condoms with spermicide, documented surgical sterilization of either the subject or their partner, or abstinence.
    15. Presence of a physical, mental, or social condition likely to affect follow-up (drug addiction, terminal illness, no telephone, homeless)
    16. Anticipation of a move from the site area within six months and unwillingness to return for follow-up at a SIGHT study site
    17. Allergy to pupil dilating drops or narrow angles precluding safe dilation
    18. Presence of a condition that contraindicates general anesthesia
    19. Participation in an investigational trial within 30 days of enrollment that involved treatment with any systemic drug therapy or therapy that affects the eligible eye(s)
  • Eye Level Exclusion Criteria Exclusion

    1. Intraocular pressure currently >28 mm Hg or >30 mm Hg at any time in the past
    2. Refractive error of more than -6.00 or more than +6.00 sphere or more than 3.00 cylinder with the following exceptions:

      • Eyes with more than 6.00 D of myopia but less than 8.00 D of myopia are eligible if: 1) there are no abnormalities on ophthalmoscopy related to myopia that are associated with visual loss (such as staphyloma, retinal thinning in the posterior pole, or more than mild optic disc tilt), and 2) the individual will wear a contact lens for all perimetry examinations with the appropriate correction.
      • Eyes with more than 6.00 D of hyperopia but less than 8.00 D of hyperopia are eligible if: 1) there is an unambiguous characteristic halo of peripapillary edema as opposed to features of a small crowded disc or other hyperopic change related to visual loss determined by the Site Investigator or the Photographic Reading Center (PRC) Director (or his designate), and 2) the individual will wear a contact lens for all perimetry examinations with the appropriate correction (which can be corrected for perimetry or with the patient's own contact lens with over correction by lens at the perimeter).

      Note: Refractive error exclusion and exceptions refer to sphere not spherical equivalent, with cylinder expressed in plus format.

    3. Other disorders causing visual loss except for refractive error and amblyopia, including cells in the vitreous or iritis
    4. Large optic disc drusen on exam or known in previous history (small drusen of the disc can occur with longstanding papilledema and are allowed if not so numerous that investigator determines they are contributing to vision loss)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03501966


Contacts
Layout table for location contacts
Contact: SIGHT CC Protocol Monitor, Diana Rojas, CCRP 813-975-8690 drojas@jaeb.org
Contact: SIGHT CC Director, Stephanie DuBose, MPH, CCRP 813-975-8690 sdubose@jaeb.org

  Hide Study Locations
Locations
Layout table for location information
United States, California
University of Southern California Recruiting
Los Angeles, California, United States, 90033
Contact: Yoon Hee Kim    323-865-6935    yoonhee.kim@med.usc.edu   
Principal Investigator: Vivek Patel, MD         
NeuroEyeOrbit Institute Recruiting
Los Angeles, California, United States, 90048
Contact: Claudio Ramirez    310-469-9080    drclaudioramirez@hotmail.com   
Principal Investigator: Swaraj Bose, MD         
Stanford University Recruiting
Palo Alto, California, United States, 94303
Contact: Zhongqiu (Katherine) Li    650-725-7105    zqli@stanford.edu   
Contact: Supriya Kawale    650-497-1481    kawale@stanford.edu   
Principal Investigator: Heather Moss, MD         
United States, Colorado
University of Colorado - Anschutz Medical Campus Recruiting
Aurora, Colorado, United States, 80045
Contact: Steve Cho    720-848-2035    steve.cho@ucdenver.edu   
Principal Investigator: Prem Subramanian, MD         
United States, Connecticut
The Eye Care Group Recruiting
Orange, Connecticut, United States, 06477
Contact: Lisa Marcil    203-573-4887    lmarcil@theeyecaregroup.com   
Principal Investigator: Robert Lesser, MD         
United States, Florida
University of Miami Recruiting
Miami, Florida, United States, 33136
Contact: Potyra Rosa    305-202-4731    prosa@med.miami.edu   
Contact: Isabel Jaraba    305-243-0314    ijaraba@med.miami.edu   
Principal Investigator: Byron Lam, MD         
United States, Illinois
Northwestern Medicine Recruiting
Chicago, Illinois, United States, 60611
Contact: Crystal Santillanes    312-472-3627    crystal.santillanes1@northwestern.edu   
Contact: Nicole Seddon    312-695-0252    nreinhol@nm.org   
Principal Investigator: Nicholas Volpe, MD         
University of Illinois at Chicago Recruiting
Chicago, Illinois, United States, 60612
Contact: Roxana Toh    312-355-4866    rtoh@uic.edu   
Principal Investigator: Peter MacIntosh, MD         
United States, Iowa
University of Iowa Recruiting
Iowa City, Iowa, United States, 52242
Contact: Trina Eden    319-356-1611    trina-eden@uiowa.edu   
Contact: Michael Wall, MD    319-353-6942    michael-wall@uiowa.edu   
Principal Investigator: Jane Bailey, MD         
United States, Kansas
University of Kansas School of Medicine Recruiting
Prairie Village, Kansas, United States, 64134
Contact: Ashley Small    913-588-0105    asmall2@kumc.edu   
Principal Investigator: Thomas Whittaker, MD         
United States, Kentucky
University of Kentucky Recruiting
Lexington, Kentucky, United States, 40536
Contact: Sadia Waheed       sadia.waheed@uky.edu   
Contact: Michael Nsoesie    859-323-7452    michael.nsoesie@uky.edu   
Principal Investigator: Padmaja Sudhakar, MD         
United States, Maryland
Johns Hopkins University School of Medicine Recruiting
Baltimore, Maryland, United States, 21287
Contact: Shelley Casey    410-502-7067    scasey10@jhu.edu   
Principal Investigator: Timothy McCulley, MD         
Bethesda Neurology, LLC Recruiting
North Bethesda, Maryland, United States, 20852
Contact: Riley Kastenhuber    301-540-2700    drkatzctc@gmail.com   
Principal Investigator: David Katz, MD         
United States, Massachusetts
Brigham and Women's Hospital Not yet recruiting
Boston, Massachusetts, United States, 02115
Contact: Kristen Roe    617-525-6763    kroe@bwh.harvard.edu   
Principal Investigator: Sashank Prasad, MD         
United States, Minnesota
University of Minnesota Recruiting
Minneapolis, Minnesota, United States, 55455
Contact: Wendy Elasky    612-626-3056    waelasky@umn.edu   
Principal Investigator: Michael Lee, MD         
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Jessica Morgan    507-293-9689    morgan.jessica@mayo.edu   
Principal Investigator: John Chen, MD         
United States, Missouri
Washington University in St. Louis Recruiting
Saint Louis, Missouri, United States, 36110
Contact: Eve (Laura) Adcock    314-286-2946    adcockl@wustl.edu   
Contact: Casey Hatscher    314-747-5832    chatscher@wustl.edu   
Principal Investigator: Gregory VanStavern, MD         
Saint Louis University Recruiting
Saint Louis, Missouri, United States, 63104
Contact: Traci Christenson    314-256-3218    traci.christenson@health.slu.edu   
Sub-Investigator: Sophia Chung, MD         
Principal Investigator: Sangeeta Khanna, MD         
United States, Nebraska
University of Nebraska Medical Center Recruiting
Omaha, Nebraska, United States, 68198
Contact: Julie Sigmund    402-559-1857    julie.sigmund@unmc.edu   
Contact: Kristi Miller    402-559-1853    kristi.miller@unmc.edu   
Principal Investigator: Shannon Lynch, MD         
United States, New York
State University of New York at Stony Brook Recruiting
East Setauket, New York, United States, 11733
Contact: Ann Marie Lavorna    631-444-4485    ann.lavorna@stonybrookmedicine.edu   
Principal Investigator: Patrick Sibony, MD         
New York Eye & Ear Infirmary of Mount Sinai Recruiting
New York, New York, United States, 10003
Contact: Harriet Lloyd    212-979-4672    hlloyd@nyee.edu   
Contact: Katy Tai    212-979-4251    ktai@nyee.edu   
Principal Investigator: Rudrani Banik, MD         
New York University School of Medicine Recruiting
New York, New York, United States, 10016
Contact: Julie Giles    929-455-5118    julie.giles@nyulangone.org   
Principal Investigator: Cinthi Pillai, MD         
University of Rochester Recruiting
Rochester, New York, United States, 14642
Contact: George O'Gara    585-273-1545    george_ogara@urmc.rochester.edu   
Principal Investigator: Zoe Williams, MD         
United States, Ohio
Ohio Neuro-Ophthalmology, Orbital Disease and Oculoplastics Recruiting
Columbus, Ohio, United States, 43214
Contact: Tammy Lauderbaugh    614-827-0013    lauderbaught@ohpin.com   
Principal Investigator: Steven Katz, MD         
United States, Oklahoma
Dean McGee Eye Institute Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Shannon Almeida    405-271-6307    shannon-almeida@dmei.org   
Principal Investigator: Anil Patel, MD         
United States, Pennsylvania
University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Meghan Karlik    215-662-8094    meghan.karlik@uphs.upenn.edu   
Principal Investigator: Kenneth Shindler, MD         
United States, Tennessee
Vanderbilt University Medical Center Recruiting
Nashville, Tennessee, United States, 37232
Contact: Scott Ruark    615-936-1639    scott.ruark@vumc.org   
Contact: Megan Barrett       megan.c.barrett.1@vumc.org   
Principal Investigator: Reid Longmuir, MD         
United States, Texas
Neuro-Eye Clinical Trials-Houston Not yet recruiting
Houston, Texas, United States, 77005
Contact: Alonso Prusmack    713-480-0218    aprusmack@neuroeye.com   
Contact: Francisco Sanchez    713-480-0218    fsanchez@neuroeye.com   
Principal Investigator: Rosa Tang, MD         
United States, Utah
University of Utah Recruiting
Salt Lake City, Utah, United States, 84132
Contact: Barbara Hart    801-581-6459    barbara.hart@hsc.utah.edu   
Contact: Kara Halsey    801-213-2034    kara.halsey@utah.edu   
Principal Investigator: Kathleen Digre, MD         
United States, Virginia
University of Virginia Recruiting
Charlottesville, Virginia, United States, 22904
Contact: Ashton Leone    434-243-5737    aml7q@virginia.edu   
Contact: Allison Weiderhold    434-243-2921    alw5rm@virginia.edu   
Principal Investigator: Steven Newman, MD         
Virginia Commonwealth University Recruiting
Richmond, Virginia, United States, 23298
Contact: Jeneane Henry    804-828-7802    jeneane.henry@vcuhealth.org   
Principal Investigator: Scott Haines, MD         
United States, Washington
Swedish Medical Center Recruiting
Seattle, Washington, United States, 98122
Contact: Meghann Long    206-215-2843    meghann.long@swedish.org   
Contact: Desiree Iriarte       desiree.Iriarte@swedish.org   
Principal Investigator: Steven Hamilton, MD         
United States, Wisconsin
University of Wisconsin Recruiting
Madison, Wisconsin, United States, 53705
Contact: Angie Adler    608-265-7557    amadler1@wisc.edu   
Principal Investigator: Yanjun (Judy) Chen, MD         
Canada, Alberta
University of Calgary Not yet recruiting
Calgary, Alberta, Canada, T2V 1P9
Contact: Emi Sanders    403-955-7942    emi.sanders@albertahealthservices.ca   
Principal Investigator: Suresh Subramaniam, MD         
Canada, Ontario
Sunnybrook Health Science Center Not yet recruiting
Toronto, Ontario, Canada, M4N 3M5
Contact: Charlene Muller    416-480-5091    charlene.muller@sunnybrook.ca   
Principal Investigator: Arun Sundaram, MD         
Puerto Rico
Rivera, Enrique J Recruiting
Bayamón, Puerto Rico, 00961
Contact: Gerardine Meléndez    787-630-4816    gmelendez2017@gmail.com   
Principal Investigator: Enrique Rivera, MD         
Sponsors and Collaborators
Jaeb Center for Health Research
National Eye Institute (NEI)
University of Iowa
Icahn School of Medicine at Mount Sinai
Investigators
Layout table for investigator information
Study Director: Michael Wall, MD University of Iowa
  Study Documents (Full-Text)

Documents provided by Jaeb Center for Health Research:
Informed Consent Form  [PDF] October 1, 2018


Layout table for additonal information
Responsible Party: Jaeb Center for Health Research
ClinicalTrials.gov Identifier: NCT03501966     History of Changes
Other Study ID Numbers: SIGHT
1U10EY025990-01A1 ( U.S. NIH Grant/Contract )
First Posted: April 18, 2018    Key Record Dates
Last Update Posted: March 13, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Jaeb Center for Health Research:
headache
idiopathic intracranial hypertension (IIH)
shunt
fenestration
acetazolamide
visual loss
diamox

Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Intracranial Hypertension
Pseudotumor Cerebri
Vascular Diseases
Cardiovascular Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Acetazolamide
Anticonvulsants
Carbonic Anhydrase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Diuretics
Natriuretic Agents
Physiological Effects of Drugs